Fruchart J C, Duriez P
SERLIA et INSERM U325, Institut Pasteur, Lille, France.
C R Seances Soc Biol Fil. 1995;189(5):889-97.
Apolipoprotein C-III (apo C-III) is present in the plasma in apo B containing lipoprotein (apo C-III-LpB) and in non apo B containing lipoprotein (apo C-III-Lp non B). Apo C-III inhibits the lipolysis of triglyceride riche particles and the apo B containing lipoprotein binding to the LDL receptor. A clinical study in myocardial infarction survivors (ECTIM study) shows that apo C-III-LpB is a good marker of atherogenesis. Hypolipidemic drugs as fenofibrate and Maxepa decrease the apo C-III-LpB particles. These studies demonstrate that apo C-III presents an important role in apo B containing lipoprotein particles metabolism and atherogenesis. Furthermore apo C-III levels may be reduced by hypolipidemic drugs.
载脂蛋白C-III(apo C-III)存在于血浆中,存在于含载脂蛋白B的脂蛋白(apo C-III-LpB)和不含载脂蛋白B的脂蛋白(apo C-III-Lp非B)中。Apo C-III抑制富含甘油三酯颗粒的脂解作用以及含载脂蛋白B的脂蛋白与低密度脂蛋白受体的结合。一项针对心肌梗死幸存者的临床研究(ECTIM研究)表明,apo C-III-LpB是动脉粥样硬化形成的良好标志物。降血脂药物如非诺贝特和Maxepa可减少apo C-III-LpB颗粒。这些研究表明,apo C-III在含载脂蛋白B的脂蛋白颗粒代谢和动脉粥样硬化形成中起重要作用。此外,降血脂药物可能会降低apo C-III水平。